Holen Sie sich die Stockscreener-App
44.51
1.09%
-0.49
Schlusskurs vom Vortag:
$45.00
Offen:
$45.94
24-Stunden-Volumen:
1.14M
Relative Volume:
1.30
Marktkapitalisierung:
$3.16B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-170.73M
KGV:
-16.53
EPS:
-2.6921
Netto-Cashflow:
$-159.70M
1W Leistung:
+2.79%
1M Leistung:
+23.26%
6M Leistung:
-28.73%
1J Leistung:
+105.87%
1-Tages-Spanne:
$44.35
$47.24
1-Wochen-Bereich:
$41.71
$47.24
52-Wochen-Spanne:
$15.80
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Firmenname
Structure Therapeutics Inc Adr
Sektor
Branche
Telefon
(650) 457-1978
Adresse
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
44.51 | 3.16B | 0 | -170.73M | -159.70M | -2.6921 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-03-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-05-02 | Eingeleitet | Citigroup | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-21 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-07-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-28 | Eingeleitet | Guggenheim | Buy |
| 2023-02-28 | Eingeleitet | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | SVB Securities | Outperform |
Alle ansehen
Structure Therapeutics Inc Adr Aktie (GPCR) Neueste Nachrichten
Shareholders Approve Directors, Auditors at 2026 Meeting - TipRanks
Director at Structure Therapeutics (NASDAQ: GPCR) gets 39,453 options - Stock Titan
Structure Therapeutics (GPCR) director receives 39,453 share options at $15 - Stock Titan
[Form 4] Structure Therapeutics Inc. Insider Trading Activity - Stock Titan
Structure Therapeutics (GPCR) grants 39,453-share option award to director - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) reports 2026 shareholder voting outcomes - Stock Titan
(GPCR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock? - TradingView
Why Structure Therapeutics’ Hot Obesity Stock Is Suddenly Sinking - TipRanks
H.C. Wainwright cuts Structure Therapeutics stock price target to $70 By Investing.com - Investing.com Canada
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs? - TradingView
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Pfizer (PFE) and Novo Nordisk (NVO) - The Globe and Mail
Why Structure Therapeutics Shares Are Suddenly Sinking - TipRanks
Structure Therapeutics Maintained at Buy as Analyst Highlights Best-in-Class Oral GLP-1 Profile and Keeps $145 Price Target Unchanged - TipRanks
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity - The Manila Times
Why Structure Therapeutics Stock Is Sliding Today - TipRanks
Zevra Therapeutics (NASDAQ: ZVRA) vote keeps classified board structure - Stock Titan
Oral obesity drug helped people lose up to 16% body weight in trial - Stock Titan
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s? - TradingView
LLY Rises 14% in a Month: Should You Hold as Obesity Growth Continues? - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why Structure Therapeutics Stock Is Surging Higher - TipRanks
Structure Therapeutics IncADR (GPCR) News, Articles, Events & Latest Updates - Stocktwits
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), AngioDynamics (ANGO) - The Globe and Mail
LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst? - TradingView
Analysts Offer Insights on Healthcare Companies: Agilent (A), Apogee Therapeutics (APGE) and Pfizer (PFE) - The Globe and Mail
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million - AOL.com
Hear Structure Therapeutics at Jefferies and Goldman Sachs healthcare talks - Stock Titan
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth? - TradingView
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position - AOL.com
Why (GPCR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Why Structure Therapeutics Shares Are Sinking Today - TipRanks
Monashee Reduces Stake in Structure Therapeutics Amid Competitive Landscape - Intellectia AI
Monashee Scales Back Its Bet on Structure Therapeutics - Yahoo Finance
HighVista Strategies Sells 69,092 Shares of Structure Therapeutics in Q1 2026News and Statistics - IndexBox
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million - The Globe and Mail
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million - The Motley Fool
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR) - The Globe and Mail
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure? - TradingView
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail
Understanding Momentum Shifts in (GPCR) - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Siemens Healthineers AG (OtherSEMHF) and BioNTech SE (BNTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Cantor Fitzgerald - The Globe and Mail
NVO Rallies 21% in a Month: How Should Investors Play the Stock? - TradingView
Brokers Offer Predictions for GPCR Q1 Earnings - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
GPCR Structure posts massive EPS miss as losses widen; stock barely flinches, down 0.13%.Product Revenue - Newser
Structure Therapeutics ADA Data Could Reframe Oral Obesity And Diabetes Prospects - Sahm
Structure Therapeutics Reports 16% Weight Loss With Oral GLP-1RA Aleniglipron in Phase 2, Prepares for Phase 3 Obesity Trial and ADA 2026 Data Presentations - Minichart
Analysts’ Top Healthcare Picks: Addus Homecare (ADUS), Aardvark Therapeutics, Inc. (AARD) - The Globe and Mail
Finanzdaten der Structure Therapeutics Inc Adr-Aktie (GPCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):